Opaleye Management Inc.

13F Portfolio Filings

Most recent 13F
Q2 2024
Location
Boston, MA
CIK
0001595855
All SEC filings
View on sec.gov
Holdings Value
Quarter Holdings Value ($000) Top Holdings Form Type Date Filed Filing ID
Q2 2024 51 437,656 HROW, TGTX, OCUL, RYTM 13F-HR 8/14/2024 000149315224032150
Q1 2024 52 458,857 OCUL, HROW, TGTX, KROS RESTATEMENT 5/29/2024 000149315224021780
Q4 2023 47 376,066 HROW, TGTX, SLRN, RYTM 13F-HR 2/14/2024 000149315224006653
Q3 2023 41 307,379 HROW, SLRN, OCUL, TGTX 13F-HR 11/14/2023 000149315223041364
Q2 2023 47 418,066 SLRN, HROW, OCUL, TELA 13F-HR 8/14/2023 000149315223028636
Q1 2023 41 333,877 HROW, OCUL, TELA, RYTM 13F-HR 5/15/2023 000149315223016769
Q4 2022 40 287,572 HROW, TELA, RYTM, OCUL 13F-HR 2/10/2023 000149315223004277
Q3 2022 42 242,132 HROW, OCUL, RYTM, TELA 13F-HR 11/14/2022 000149315222032068
Q2 2022 47 221,854 HROW, OCUL, CDXS, CRNX 13F-HR 8/15/2022 000149315222022856
Q1 2022 45 321,998 OCUL, CDXS, CMRX, HROW 13F-HR 5/16/2022 000149315222013764
Q4 2021 39 471,486 CDXS, OCUL, CMRX, CLDX 13F-HR 2/14/2022 000149315222004434
Q3 2021 48 535,390 OCUL, CLDX, CDXS, CMRX 13F-HR 11/15/2021 000149315221028799
Q2 2021 48 602,060 OCUL, CMRX, CLDX, BBIO 13F-HR 8/16/2021 000149315221020260
Q1 2021 58 680,804 OCUL, CMRX, TARA, BBIO 13F-HR 5/17/2021 000149315221012017
Q4 2020 59 765,570 OCUL, TARA, EIDOS THERAPEUTICS INC, ETON 13F-HR 2/12/2021 000149315221003697
Q3 2020 55 511,320 OCUL, TARA, ETON, CRDF 13F-HR 11/16/2020 000149315220021694
Q2 2020 48 495,150 TARA, OCUL, NLTX, CHEMOCENTRYX INC 13F-HR 8/14/2020 000149315220015902
Q1 2020 44 377,363 ARTARA THERAPEUTICS INC, FTSV, OCUL, APTO 13F-HR 5/15/2020 000149315220009140
Q4 2019 47 509,651 EPZM, APTO, CDXS, FTSV 13F-HR 2/14/2020 000149315220002529
Q3 2019 49 276,541 CDXS, STXS, EPZM, HROW 13F-HR 11/14/2019 000149315219017503
Q2 2019 43 328,094 CDXS, HROW, AXGN, EPZM 13F-HR 8/14/2019 000149315219012567
Q1 2019 53 361,134 CDXS, AXGN, EPZM, CERC 13F-HR 5/15/2019 000149315219007425
Q4 2018 47 267,975 CDXS, AXGN, LOXO, AMRN 13F-HR 2/14/2019 000149315219002114
Q3 2018 47 393,047 AXGN, CDXS, LOXO, AMRN 13F-HR 11/14/2018 000149315218016123
Q2 2018 36 386,358 AXGN, LOXO, CDXS, FGEN 13F-HR 8/14/2018 000149315218011830
Q1 2018 38 349,747 AXGN, BPMC, LOXO, CDXS 13F-HR 5/14/2018 000149315218006822
Q4 2017 35 312,298 AXGN, BPMC, FGEN, LOXO 13F-HR 2/9/2018 000149315218001743
Q3 2017 34 282,772 BPMC, AXGN, FGEN, IMMU 13F-HR 11/14/2017 000149315217013210
Q2 2017 41 239,398 BPMC, AXGN, FGEN, LOXO 13F-HR 8/14/2017 000149315217009239
Q1 2017 44 200,928 BPMC, AXGN, FGEN, NOVELION THERAPEUTICS INC 13F-HR 5/15/2017 000149315217005196
Q4 2016 40 169,717 BPMC, AXGN, ARIA, AEVI GENOMIC MEDICINE INC 13F-HR 2/21/2017 000114420417010166
Q3 2016 44 191,082 BPMC, AXGN, ARIA, MDGN 13F-HR 11/14/2016 000154692716000542
Q2 2016 49 149,709 AXGN, MDGN, ARIA, FGEN RESTATEMENT 8/12/2016 000154692716000514
Q1 2016 52 160,362 AXGN, ARIA, RARE, FGEN RESTATEMENT 5/27/2016 000154692716000499
Q4 2015 53 239,178 RARE, AXGN, FGEN, GERN 13F-HR 2/12/2016 000154692716000408
Q3 2015 49 203,221 CMRX, RARE, MLNT, AXGN 13F-HR 11/13/2015 000154692715000281
Q2 2015 46 251,326 CMRX, MLNT, TVTX, AMAG 13F-HR 8/14/2015 000154692715000231
Q1 2015 37 215,386 CMRX, MLNT, ARIA, TVTX 13F-HR 5/15/2015 000154692715000149
Q4 2014 36 197,898 CMRX, AGIO, MLNT, TVTX 13F-HR 2/13/2015 000154692715000070
Q3 2014 30 128,295 CMRX, PCYC, TVTX, ARIA 13F-HR 11/14/2014 000154692714000196
Q2 2014 27 115,981 CMRX, TVTX, ARIA, PCYC 13F-HR 8/14/2014 000154692714000159
Q1 2014 30 135,373 TVTX, ARIA, CMRX, PCYC 13F-HR 5/15/2014 000154692714000115
Q4 2013 23 127,387 GENTIUM S P A, GERN, PCYC, ARIA 13F-HR 2/14/2014 000154692714000060
Additional filings from Opaleye Management Inc. that have since been restated